KALA BIO, Inc. (KALA) |
| 0.9633 -0.127 (-11.62%) 07-14 16:00 |
| Open: | 1.11 |
| High: | 1.11 |
| Low: | 0.9345 |
| Volume: | 237,740 |
| Market Cap: | 21(M) |
| PE Ratio: | -0.34 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 3.71 |
| Resistance 1: | 2.65 |
| Pivot price: | 1.83 |
| Support 1: | 0.93 |
| Support 2: | 0.78 |
| 52w High: | 1030 |
| 52w Low: | 0.9345 |
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Financials
| EPS | -89.070 |
| Book Value | 0.580 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -69.3 |
| Return on Equity (ttm) | -238.7 |
Company news
Mon, 13 Jul 2026
KALA Stock Hits Record Low – Firm Announces Reverse Split After Shares Fail To Surpass The $1 Mark - Stocktwits
Thu, 02 Jul 2026
David Lazar trims KALA BIO (KALA) stake to 3.9% with 719,404 shares - Stock Titan
Fri, 26 Jun 2026
[EFFECT] KALA BIO, Inc. SEC Filing - Stock Titan
Thu, 25 Jun 2026
Enterprise value to revenue forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
Thu, 07 May 2026
Kala Bio announces 1-for-50 reverse stock split effective Friday - Investing.com
Thu, 07 May 2026
KALA BIO Announces Reverse Stock Split - GlobeNewswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
